Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 7, Number 2—April 2001
THEME ISSUE
4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections

Introduction

Emergence of Vancomycin-Resistant Enterococci

Louis B. RiceComments to Author 
Author affiliation: VA Medical Center and Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

Main Article

Table 2

Antibiotic treatment and persistence of high-level colonization with vancomycin and ampicillin-resistant Enterococcus faecium C68 (47)

Approximate log10 CFU VRE/g stoola

Day 0
Day 4-5
Day 9-10
Day 14-15
Day 19-20
Saline 9.5 8.3 6 3.8 3.5
Vancomycin (SQ) >9 >9 >9 >9 >9
Vancomycin (oral) >9 >9 >9 >9 >9
Antibiotics with potent antianaerobic activity
Piperacillin-tazobactam >9 >9 >9 >9 >9
Ticarcillin-clavulanic acid >9 >9 >9 >9 >9
Clindamycin >9 >9 >9 >9 >9
Cefotetan >9 >9 8.8 7.8 8
Metronidazole >9 >9 >9 >9 >9
Ampicillin >9 >9 8 7.2 7
Ampicillin-sulbactam >9 >9 >9 7.8 7.7
Antibiotic withs relatively poor activity against anaerobic bacteria
Cefepime >9 >9 6.2 5 4.8
Ceftriaxone >9 8.8 8.4 7.2 6
Aztreonam >9 9 4.3 4.2 3.8
Ciprofloxacin >9 8.8 6 5.2 5

aVRE = vancomycin-resistant enterococci.; SQ = subcutaneous

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO